Sanli Pharmaceutical issued a preliminary earnings decline announcement for the first half of 2026, expecting attributable net profit of 32 million to 45 million yuan, a year-on-year decrease of 45.82% to 61.47%. The company stated that, affected by the deepening of DRG/DIP medical insurance payment reforms and changes in market conditions, the traditional Chinese medicine segment continues to face overall performance pressure, and the prosperity of industries related to its main business fell short of expectations, leading to lower-than-expected product sales and a decline in profit.
Guizhou Sanli Pharmaceutical Co LtdCompany expects net profit to drop 45.82%-61.47% year-on-year due to DRG/DIP reforms and weak market conditions.